88 institutions hold shares in Ampio Pharmaceuticals Inc. (AMPE), with 14.86M shares held by insiders accounting for 7.60% while institutional investors hold 13.00% of the company’s shares. The shares outstanding are 187.20M, and float is at 170.94M with Short Float at 11.64%. Institutions hold 12.01% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 7.08 million shares valued at $11.26 million. The investor’s holdings represent 3.62% of the AMPE Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 3.1 million shares valued at $4.94 million to account for 1.59% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 1.24 million shares representing 0.63% and valued at over $1.97 million, while Willis Investment Counsel, Inc. holds 0.62% of the shares totaling 1.21 million with a market value of $1.93 million.
Ampio Pharmaceuticals Inc. (AMEX: AMPE) is 1.26% higher on its value in year-to-date trading and has touched a low of $0.36 and a high of $2.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMPE stock was last observed hovering at around $1.66 in the last trading session, with the day’s loss setting it -0.05% off its average median price target of $4.00 for the next 12 months. It is also 59.75% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 59.75% higher than the price target low of $4.00 for the same period.
Currently trading at $1.61, the stock is -3.88% and -8.81% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.26 million and changing -3.01% at the moment leaves the stock 39.55% off its SMA200. AMPE registered 272.69% gain for a year compared to 6-month gain of 70.35%. The firm has a 50-day simple moving average (SMA 50) of $1.8194 and a 200-day simple moving average (SMA200) of $1.3388.
The stock witnessed a -5.85% loss in the last 1 month and extending the period to 3 months gives it a -24.06%, and is -11.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.21% over the week and 11.33% over the month.
Distance from 52-week low is 351.87% and -45.97% from its 52-week high.
Ampio Pharmaceuticals Inc. (AMPE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ampio Pharmaceuticals Inc. (AMPE) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ampio Pharmaceuticals Inc. is expected to release its quarterly report on 06/02/2021 and quarterly earnings per share for the current quarter are estimated at -$0.02.The EPS is expected to grow by 11.90% this year.
Ampio Pharmaceuticals Inc. (AMPE) Insider Activity
A total of 9 insider transactions have happened at Ampio Pharmaceuticals Inc. (AMPE) in the last six months, with sales accounting for 2 and purchases happening 7 times. The most recent transaction is an insider sale by STOKELY DAN, the company’s CFO. SEC filings show that STOKELY DAN sold 40,000 shares of the company’s common stock on Mar 16 at a price of $1.83 per share for a total of $73048.0. Following the sale, the insider now owns 28315.0 shares.
Ampio Pharmaceuticals Inc. (AMPE): Who are the competitors?
The company’s main competitors (and peers) include Aerie Pharmaceuticals Inc. (AERI) that is trading 32.72% up over the past 12 months and Johnson & Johnson (JNJ) that is 34.82% higher over the same period. Flexion Therapeutics Inc. (FLXN) is 2.31% up on the 1-year trading charts. Short interest in the company’s stock has fallen -8.2% from the last report on Feb 11, 2021 to stand at a total of 21.52 million short shares sold with a short interest ratio of 6.77.